The Post Roll: Earnings – Aphria, Organigram, Aurora & Valens Thomas George·April 15, 2020Grizzle reviews the latest earnings results of Aphria, Organigram and Valens. Also they examine the impact of the...Marijuana Analysis·15 Comments·
Aphria Demonstrates Early Cannabis 2.0 Success with Q3 Revenue Beat Scott Willis·April 15, 2020Aphria earnings were a rare bright spot in an otherwise gloomy Canadian cannabis landscape. Aphria along with Village...Marijuana Analysis·4 Comments·
The Post-Roll: Bull Market for Vice (Booze, Smokes and Pot) Scott Willis·April 10, 2020People consumer more pot, booze and smokes when stuck at home. Here are the stocks to own to...Marijuana Analysis·7 Comments·
Marijuana Investor Roundup: Analysis of the Week’s Most Important Events (Jan 25th, 2020) Andy Zhou·January 25, 2020We cover only the news that directly impacts your marijuana stocks portfolio. All the rest is just noise....Marijuana News·3 Comments·
Aphria Receives Market Stamp of Approval With New $100 Million Investment Scott Willis·January 24, 2020This significant investment demonstrates that in the eyes of the market Aphria (TSE: APHA; NYSE: APHA) is the...Marijuana News·3 Comments·
Aphria Receives EU GMP Certification as the Company Eyes Expansion into Germany Andy Zhou·January 21, 2020Aphria Inc. (NYSE: APHA) has received the EU GMP certification, allowing their German subsidiary CC Pharma to start...Marijuana News·1 Comment·
OGI Smashes Expectations But Actual Results are a House of Cannabis Horrors. Scott Willis·January 14, 2020Organigram (OGI) beat lowered analyst estimates but dig a little deeper and the big stock price spike looks like a complete headfake.Marijuana Analysis·1 Comment·
Aphria (APHA) Earnings – Guidance Cut But Still the Best Game in Town Scott Willis·January 14, 2020Aphria has the cash to weather the coming storm and the profitability to match. The only safe haven in Canadian cannabis.Marijuana Analysis·1 Comment·
GW Pharmaceuticals Releases a Q4 Revenue Beat, but Will the Rapid Growth Continue? Scott Willis·January 13, 2020GW Pharmaceuticals' (NASDAQ: GWPH) 7% revenue beat was cheered by the markets, but with revenue growth slowing can...Marijuana News·0 Comments·
